viewAmryt Pharma PLC

Amryt Pharma raises $40M in private placement from new and existing specialist biotech investors

Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies.

Wiley says investors include Stonepine Capital, Aquilo Capital Management, Amati Global Investors, Athyrium Capital Management, and Highbridge Capital Management. What's more, the firm has received marketing approval from the authorities in Brazil for its specialist cholesterol drug Lojuxta.

Quick facts: Amryt Pharma PLC

Price: 212 GBX

Market: AIM
Market Cap: £379.06 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...


Market Report: FTSE flies as Boris travels to Brussels for last ditch Brexit...

FTSE 100 made a strong start on hopes Boris flying off for last-ditch talks might conjure up a last-ditch Brexit deal. London’s blue-chip index rose 50 to 6,608. Tesco said it will be free to pay a £5bn special dividend to investors towards the end of February 2021 after all the...

on 9/12/20

2 min read